SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-028288
Filing Date
2024-06-14
Accepted
2024-06-14 16:08:40
Documents
13
Period of Report
2024-06-13
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K gthx-20240613.htm   iXBRL 8-K 46587
  Complete submission text file 0001628280-24-028288.txt   174506

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT gthx-20240613.xsd EX-101.SCH 1922
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT gthx-20240613_lab.xml EX-101.LAB 22548
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT gthx-20240613_pre.xml EX-101.PRE 13060
16 EXTRACTED XBRL INSTANCE DOCUMENT gthx-20240613_htm.xml XML 2833
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38096 | Film No.: 241044801
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)